AbbVie is reportedly buying Apogee Therapeutics for about $11 billion, adding a late‑stage eczema drug and deepening its immunology pipeline in North Chicago.

Booz Allen is acquiring Austin's Ultra I&C Mission Solutions for about $720M, adding hundreds of engineers and battlefield-ready software, edge compute and encryption tools.

UT Austin engineers turned a hydrogel textile into a jacket that harvests drinkable water from the air — tests show survival-scale yields and a path toward commercialization.

SpaceX has agreed to provide Reflection AI with GB300-class compute at its Colossus campus near Memphis in a deal that could reach $6.3 billion.

A University of Minnesota rodent study found unilateral DBS sped decision‑making as effectively as bilateral stimulation, strengthening the case for simpler adaptive implants.

SpaceX is aiming for a predawn Falcon 9 launch from Cape Canaveral on June 23 to fly its Starfall demo, a prototype reentry capsule the FAA cleared for testing. The booster will try to return to a droneship off the Atlantic coast.

A startup servicer called Link is being prepped near Washington to rendezvous with and reboost the Neil Gehrels Swift Observatory. Rapid tests and full-scale rehearsals are underway as launch approaches later this month.

Gene‑edited GalSafe pigs remove the sugar that causes some red‑meat allergies and have FDA clearance. Limited pork is being shared with patients while regulators and ethicists debate next steps.

Edged US opened a 36 MW, waterless AI data center in Mesa, promising to eliminate operational water use while delivering high-density compute and local jobs.

Blocking an age‑linked enzyme regenerated hyaline cartilage in mice and produced early repair signals in human knee tissue, researchers report.

A new NIH-backed AI data center at the UH Cancer Center will develop more representative medical datasets to improve care across Hawaiʻi and the Pacific. Local leaders say the compact lab could unlock major research dollars for Honolulu.

San Diego’s cAMPfield closed a $180M Series A to advance prifemilast, a once‑daily oral PDE4B inhibitor, into global trials for IBD.

A tiny peptide called BRP cut meals in mice and minipigs and drove fat‑specific weight loss; human testing is not yet underway.